Visceral pleural invasion is associated with post-operative poor prognosis of 261 Chinese patients w

来源 :第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 | 被引量 : 0次 | 上传用户:m397760109
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Objective: To determine the association between visceral pleural invasion (VPI) and post-operative prognosis in early stage non-small cell lung cancer (NSCLC).Method: Between November 2007 and November 2011, 261 NSCLC patients (pathological stages Ⅰ or Ⅱ) underwent radical resection in the First Affiliated Hospital of Jilin University.The associations between VPI and survival rates of these patients were retrospectively analyzed.Result: The one-year overall survival (OS) of patients with or without VPI were similar (90.77% and 93.13%).
其他文献
Objective:This Phase Ⅰ study evaluated the safety, tolerability, and clinical activity ofpembro, a selective anti-PD-1 antibody that blocks the interaction between programmed death-1 (PD-1) on T-cells
会议
Objective: We conducted a retrospective study to evaluate the role of prophylactic cranial irradiation (PCI) on patients with surgically resected small cell lung cancer(SCLC).Method: The records of co
会议
Objective: A recent phase 3 study (PARAMOUNT) demonstrated that continuation maintenance therapy of pemetrexed is a new treatment paradigm for advanced nonsquamous NSCLC.The majority of patients enrol
会议
Objeetive: NSCLC are particularly aggressive tumors, with high invasive properties and metastatic potential.About 40% stage Ⅰ and 60% stage Ⅱ NSCLC patients are dying of distant metastases within 5 ye
会议
Objective:To identify the feasibility of pleural effusion detection of epidermal growth factor receptor (EGFR) mutations, echinoderm microtubule-associated protein like 4 (EML4)-anaplastic lymphoma ki
会议
背景:厄洛替尼已获FDA批准用于表皮生长因子受体突变(EGFR MT)的非小细胞肺癌(NSCLC)一线治疗,中位无进展生存期(PFS)为10.4个月.Nivolumab是全人源化IgG4程序性死亡1(PD-1)免疫检查点抑制剂抗体,作为单药治疗晚期NSCLC患者显示了出令人鼓舞的安全性与生存获益.临床前数据支持EGFR路径活化PD-L1表达与免疫逃避在EGFR驱动的肺肿瘤中的作用.本摘要将报告评估
会议
Objective:Programmed death-1 (PD-1) receptor-ligand interaction inhibits T cell activation against tumor cells.Pembro is a potent and highly selective humanized monoclonal antibody against PD-1 design
会议
Objective: Cancer stem cells (CSCs) are believed to cause local recurrence, distant metastasis, radiotherapy and chemotherapy resistance.We hypothesized that genetic variation in CD133 (the official n
会议
Objective: A meta-analysis was recently conducted in East-Asian advanced non-squamous non-small cell lung cancer (nsq-NSCLC) patients based on available individual patient data from three randomized p
会议
Objective: Pemetrexed in combination with platinum has shown better efficacy and less toxicity than other standard first-line chemotherapies for patients with advanced non-squamous non-small cell lung
会议